Biogen, Eisai in Alzheimer's pact

Share this article:

Biogen Idec and Tokyo-based Eisai announced today that they will collaborate and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401. E2609 has completed Phase-I trials. BAN2401 is now recruiting for Phase II.

The agreement also includes an option to jointly develop and commercialize two of Biogen Idec's candiates for Alzheimer's, anti-amyloid beta antibody BIIB037, currently in Phase I, and an anti-tau monoclonal antibody.

Biogen CEO George Scangos stated, "Eisai's candidates have demonstrated compelling early data and complement our AD research while extending our pipeline in this critical area." 

Eisai will act as the operational and regulatory lead for both E2609 and BAN2401, and as its role suggests, will pursue marketing authorization for both compounds.

The companies will share costs, including R&D expenses, and Eisai retains all potential sales for E2609 and BAN2401, but profits will be split between the two. In the US and EU, Eisai and Biogen will co-promote the products, if approved.

Biogen will provide Eisai with an up-front payment, as well as development, approval and commercial milestone payments.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.